Physician profile
Ira M Jaffe
NPI 1548274210
$1,652.84
in general payments reported to CMS, 2019-2025
20 companies · $221 in 2025
The $221 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $309 · 2020: $268 · 2021: $317 · 2022: $246 · 2023: $170 · 2024: $123 · 2025: $221.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $513.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $513.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Roche Diagnostics Corporation | $419.26 | 2019-2020 | |
| Coopersurgical, INC. | $369.52 | 2022-2025 | Paragard T 380a, Paragard T 380a |
| Becton, Dickinson and Company | $261.75 | 2021 | |
| Evofem Biosciences, INC. | $82.88 | 2022-2025 | Phexxi, Solosec, Phexx |
| Exeltis, USA INC. | $81.80 | 2020-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $64.19 | 2019-2025 | |
| Exact Sciences Corporation | $61.04 | 2023-2024 | Cologuard Collection Kit |
| Takeda Pharmaceuticals U.S.A., INC. | $60.18 | 2022-2023 | Vpriv |
| Astellas Pharma US INC | $44.63 | 2019-2023 | Veozah |
| Lilly USA, LLC | $38.86 | 2023 | Mounjaro |
| Seqirus USA INC | $29.04 | 2025 | Flucelvax, Fluad |
| Mayne Pharma Commercial LLC | $20.46 | 2022 | |
| Abbvie INC. | $18.37 | 2020 | |
| Biogen, INC. | $16.42 | 2025 | Zurzuvae |
| Hologic Sales and Service, LLC | $16.32 | 2021 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Millicent US INC | $15.72 | 2020 | |
| Merck Sharp & Dohme LLC | $15.48 | 2019 | |
| Agile Therapeutics, INC. | $13.62 | 2021 | |
| Amag Pharmaceuticals, INC. | $11.87 | 2019 | |
| Daiichi Sankyo INC. | $11.43 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ira Jaffe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.